Lannett Company has signed a definitive agreement to acquire privately held Silarx Pharmaceuticals, a manufacturer and marketer of liquid generic pharmaceutical products. The transaction is expected to close in early June 2015. Strategic benefits of the acquisition include an FDA-approved manufacturing facility, research and development expertise and added diversity to Lannett’s portfolio of existing and pipeline products. “We look forward to welcoming Silarx to the Lannett family,” said Arthur...